Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid beta-Associated Cognitive Decline in Older Adults
Christa Dang, Karra D Harrington, Yen Ying Lim, David Ames, Jason Hassenstab, Simon M Laws, Nawaf Yassi, Martha Hickey, Stephanie R Rainey-Smith, Joanne Robertson, Christopher C Rowe, Hamid R Sohrabi, Olivier Salvado, Michael Weinborn, Victor L Villemagne, Colin L Masters, Paul Maruff
Archives of Clinical Neuropsychology | OXFORD UNIV PRESS | Published : 2019
Objective: To prospectively examine 8-year risk of clinical disease progression to mild cognitive impairment (MCI)/dementia in older adults ≥60 with superior episodic memory (SuperAgers) compared to those cognitively normal for their age (CNFA). Additionally, to determine the extent to which SuperAgers were resilient to the negative effects of elevated amyloid-beta (Aβ+) on cognition. Method: Participants were classified as SuperAgers based on episodic memory performance consistent with younger adults aged 30-44 and no impairment on non-memory tests (n = 179), and were matched with CNFA on age, sex, education, and follow-up time (n = 179). Subdistribution hazard models examined risk of clini..View full abstract
Awarded by Dementia Collaborative Research Centres program
CD is a recipient of the Melbourne Research Scholarship. Funding for the AIBL study was provided in part by the study partners [Australian Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research Institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, CogState Ltd., Hollywood Private Hospital, Sir Charles Gardner Hospital]. The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as ongoing funding from the Science and Industry Endowment Fund (SIEF).